DBP.B: Revenue and net loss improved, with strong project progress and a major rights issue launched

About this update from Double Bond Pharmaceutical International Ab Class B

Revenue and net results improved significantly year-over-year, driven by progress in key projects and new partnership opportunities. A major rights issue was launched, and the company is accelerating development of its pipeline, especially S1053 and SA033.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Double Bond Pharmaceutical International Ab Class B